Clinical Trials Logo

Malignant Hepatobiliary Neoplasm clinical trials

View clinical trials related to Malignant Hepatobiliary Neoplasm.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05068739 Completed - Biliary Stricture Clinical Trials

Needle Knife Fistulotomy Versus Partial Ampullary Endoscopic Mucosal Resection for Difficult Biliary Cannulation

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

The aims of this study are to compare the needle knife fistulotomy (NKF) technique versus the partial ampullary endoscopic mucosal resection (PA-EMR) technique in patients with difficult biliary cannulation and to assess the incidence rate of complications between these cannulation methods.

NCT ID: NCT03112668 Completed - Clinical trials for Stage IV Breast Cancer

Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners

Start date: December 6, 2017
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well acceptance and commitment therapy works in improving well-being in patients with stage III-IV cancer and their partners. Learning how to accept negative thoughts and feelings and how to live in the present without worrying about the future or past may improve coping skills in patients with stage III-IV cancer and their partners.

NCT ID: NCT02916199 Completed - Pancreatic Diseases Clinical Trials

Primary Needle Knife Fistulotomy Versus Conventional Cannulation Method

Start date: October 4, 2016
Phase: N/A
Study type: Interventional

The aim of this study are to evaluate the feasibility of needle knife fistulotomy (NKF) as an initial procedure for biliary access in patients with biliary disease who are at increased risk for post-endoscopic retrograde endoscopic retrograde cholangiopancreatography (PEP) and to assess the incidence rate of complications including PEP between NKF and conventional cannulation methods.

NCT ID: NCT02265341 Completed - Clinical trials for Malignant Hepatobiliary Neoplasm

Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

Start date: December 2014
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well ponatinib hydrochloride works in treating patients with biliary cancer that has spread to other places in the body and that have alterations (fusions) in a gene known as fibroblast growth factor receptor 2 (FGFR2). Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.